CIDP (chronic inflammatory demyelinating polyneuropathy) trials in Poland
11 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
- Where
- Cracow, Katowice, Lublin, Warsaw, Warszawa
- Age
- 18 years and over
- People
- 160 worldwide
- Run by
- argenx
See details and how to joinNCT07091630 · EU 2025-520805-10-00 - Phase 2/3Taking peopleEfficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Where
- Lublin, Poznan
- Age
- 18 years and over
- People
- 201 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05327114 · EU 2023-508425-28-00 - Phase 3Taking peopleA Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
- Where
- Bydgoszcz, Cracow, Katowice, Lublin, Poznan, Rzeszow, Szczecin, Warsaw, Warszawa
- Age
- 18 years and over
- People
- 218 worldwide
- Run by
- argenx
See details and how to joinNCT06920004 · EU 2024-520097-36-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
- Where
- Bydgoszcz, Krakow, Lodz, Lublin, Warsaw, Wroclaw
- Age
- 18 years to 75 years
- People
- 256 worldwide
- Run by
- Dianthus Therapeutics
See details and how to joinNCT06858579 - Phase 3Enrolling by invitationLong-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
- Where
- Lublin
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- Sanofi
See details and how to joinNCT06859099 · EU 2024-517032-22-00 - Phase 3Taking peopleA Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Where
- Cracow, Lublin
- Age
- 18 years and over
- People
- 160 worldwide
- Run by
- Sanofi
See details and how to joinNCT06290141 · EU 2023-508338-33-00 - Phase 3Taking peopleA Phase III study to evaluate how the body processes Xembify in comparison to Gamunex-C and determine the safety and in people with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Where
- Bydgoszcz, Cracow, Katowice, Lublin, Piaseczno, Wroclaw, Wrocław
- Age
- 18 years and over
- People
- 20 worldwide
- Run by
- Grifols Therapeutics LLC
See details and how to join2025-522165-30-00 · EU 2025-522165-30-00 - Phase 3Taking peopleA Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Where
- Bydgoszcz, Katowice, Krakow, Wroclaw
- Age
- 18 years and over
- People
- 40 worldwide
- Run by
- Grifols Therapeutics LLC
See details and how to joinNCT07540221 - Phase 2Taking peopleImeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Where
- Bydgoszcz, Cracow, Katowice, Lublin, Poznan
- Age
- 18 years and over
- People
- 162 worldwide
- Run by
- Immunovant Sciences GmbH
See details and how to joinNCT07032662 · EU 2024-517614-14-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
- Where
- Bydgoszcz, Cracow, Łódź, Lublin, Warsaw, Wroclaw
- Age
- 18 years and over
- People
- 138 worldwide
- Run by
- Dianthus Therapeutics Inc.
See details and how to join2024-517529-26-00 · EU 2024-517529-26-00 - Phase 3Taking peopleA Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Where
- Cracow, Lublin, Warsaw
- Age
- 18 years and over
- People
- 59 worldwide
- Run by
- Takeda
See details and how to joinNCT06747351 · EU 2024-517450-95-00